Rights and permissions
About this article
Cite this article
Patent expiry of blockbuster biologics gives biosimilars a chance. Pharmacoecon. Outcomes News 654, 11 (2012). https://doi.org/10.2165/00151234-201206540-00036
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201206540-00036